Skip to main content

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

Completed · Phase 2 · NCT06358950

Conditions: Narcolepsy Type 1

At a glance

Research payments reported, 2025
$2.1M
U.S. investigators named
37
Sites paid
37
Planned or actual enrollment
92

About the trial

Sponsor
Alkermes, Inc.
Tested
ALKS 2680 (drug), Placebo (drug)
Dates
Started 2024-03-24; completion 2025-07-31
Results posted
Not yet

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

From ClinicalTrials.gov, last updated 2026-06-10. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Alkermes, Inc. reported $2.1M in research payments for this study in 2025 (1,177 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • The Board of Trustees of the Leland Stanford Junior University $432,969
  • Futuresearch Trials of Neurology, LLC. $136,340
  • Clinical Site PArtners, LLC. $113,758
  • Intrepid Research, LLC. $99,530
  • Sound Asleep Research, Inc. $96,059
  • Research Carolina Elite, LLC. $75,402
  • Teradan Clinical Trials $62,295
  • Bryan Medical Center, NE $61,992
  • Sleep Therapy & Research Center $56,468
  • Mayo Clinic Hospital, AZ $47,979
  • Advanced Respiratory and Sleep Medicine, PLLC $43,777
  • Osf Heart of Mary Medical Center, IL $43,626
  • University of Colorado Denver Hospital $42,829
  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $42,690
  • The Board of Regents of the University of Wisconsin System $42,496
  • Sleep Practitioners, LLC $41,875
  • Neurotrials Research, Inc. $39,821
  • Delta Waves Sleep Disorders and Research Center $37,287
  • Thomas Jefferson University $36,627
  • Neuroscience Research Center, LLC. $36,546
  • Cleveland Clinic, OH $36,214
  • Geisinger Clinic $31,676
  • Respiratory Specialists $30,134
  • Ohio Sleep Medicine and Neuroscience Institute $30,040
  • Pharmaseek, LLC. dba Wcg Site Network $29,812
  • Santa Monica Clinical Trials $29,562
  • Community Research Management Associates, Inc. $29,144
  • Bogan Sleep Consultants, LLC $28,246
  • Tricoastal Narcolepsy and Sleep Disorders Center, PLLC. $28,123
  • Clinical Research Institute $28,074
  • Neurology Clinic PC $27,024
  • Patient First MD $26,757
  • Sds Clinical Trials, Inc. $25,933
  • Pharmadev Clinical Research Institute, LLC $24,205
  • Clinical Neurophysiology Services PC $23,724
  • Comprehensive Sleep Medicine Associates Csma $20,461
  • Wake Forest University Health Sciences $16,257

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.